Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kevin Shawn Oh, M.D.

Co-Author

This page shows the publications co-authored by Kevin Oh and Andrzej Niemierko.
Connection Strength

0.980
  1. Post-operative radiation therapy to the surgical cavity with standard fractionation in patients with brain metastases. Sci Rep. 2020 04 14; 10(1):6331.
    View in: PubMed
    Score: 0.217
  2. Adjuvant Radiation Therapy Versus Surveillance After Surgical Resection of Atypical Meningiomas. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):252-266.
    View in: PubMed
    Score: 0.056
  3. Early experience with hippocampal avoidance whole brain radiation therapy and simultaneous integrated boost for brain metastases. J Neurooncol. 2020 May; 148(1):81-88.
    View in: PubMed
    Score: 0.054
  4. Atypical Histopathological Features and the Risk of Treatment Failure in Nonmalignant Meningiomas: A Multi-Institutional Analysis. World Neurosurg. 2020 Jan; 133:e804-e812.
    View in: PubMed
    Score: 0.052
  5. Volumetric and actuarial analysis of brain necrosis in proton therapy using a novel mixture cure model. Radiother Oncol. 2020 01; 142:154-161.
    View in: PubMed
    Score: 0.052
  6. Patterns of Failure Among Patients With Low-grade Glioma Treated With Proton Radiation Therapy. Pract Radiat Oncol. 2019 Jul - Aug; 9(4):e356-e361.
    View in: PubMed
    Score: 0.050
  7. Hypopituitarism After Cranial Irradiation for Meningiomas: A Single-Institution Experience. Pract Radiat Oncol. 2019 May; 9(3):e266-e273.
    View in: PubMed
    Score: 0.050
  8. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide. J Neurooncol. 2019 Mar; 142(1):69-77.
    View in: PubMed
    Score: 0.049
  9. Proton Stereotactic Radiosurgery for Brain Metastases: A Single-Institution Analysis of 370 Patients. Int J Radiat Oncol Biol Phys. 2018 07 15; 101(4):820-829.
    View in: PubMed
    Score: 0.047
  10. The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity. J Neurooncol. 2018 Jun; 138(2):299-306.
    View in: PubMed
    Score: 0.047
  11. Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas. J Neurosurg. 2018 04; 128(4):1123-1132.
    View in: PubMed
    Score: 0.045
  12. The impact of different stereotactic radiation therapy regimens for brain metastases on local control and toxicity. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):391-397.
    View in: PubMed
    Score: 0.045
  13. Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade. Neuro Oncol. 2016 06; 18(6):863-72.
    View in: PubMed
    Score: 0.040
  14. Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. J Neurosurg. 2016 Jan; 124(1):106-14.
    View in: PubMed
    Score: 0.039
  15. Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. J Neurooncol. 2015 May; 123(1):75-84.
    View in: PubMed
    Score: 0.038
  16. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro Oncol. 2015 Feb; 17(2):296-302.
    View in: PubMed
    Score: 0.037
  17. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat. 2012 Nov; 136(1):153-60.
    View in: PubMed
    Score: 0.032
  18. Outcomes after whole brain reirradiation in patients with brain metastases. Int J Radiat Oncol Biol Phys. 2012 Feb 01; 82(2):e167-72.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.